Sirona Biochem (Seite 3102)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 23.05.24 18:17:31 von
neuester Beitrag 23.05.24 18:17:31 von
Beiträge: 31.052
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 4
Gesamt: 5.406.238
Gesamt: 5.406.238
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R
0,0405
EUR
-6,90 %
-0,0030 EUR
Letzter Kurs 23.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2730 | +53,19 | |
| 18,150 | +52,78 | |
| 0,8500 | +49,10 | |
| 1,2791 | +30,51 | |
| 1,8500 | +29,37 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 48,76 | -17,68 | |
| 0,9853 | -17,89 | |
| 3,4200 | -29,63 | |
| 1,7000 | -31,17 | |
| 0,8000 | -41,18 |
Beitrag zu dieser Diskussion schreiben
Feedback
gutes Posting auf SH
SGLT2 vs Skin Lightener (beides "Produkte" von Sirona Biochem)
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
For me my main reason for first investing in Sirona was the Skin Lightener. This is a fast to market compound with very few hoops to jump through to get to approval. The SGLT2 as great of a product it is, will still be a wait till anything comes from it (wheres biotechguy when you need him lol). Ive said it many times over the last few days but one more time wont hurt...A skin lightener deal for one or both of our 2 skin lightener compunds will blow the lid off this thing. Johnson will be wondering where the hell his 4m share wall went (an assumption on my part obviously).
Rumours are that interest is VERY high for the skin compounds as some are fighting for exclusivity of one of them. Depending on the timing for a deal, SBM wont need dilution as I see this bringing alot of money in up front and much more in royalty payments...CCH and J&J connection maybe? I dunno but dont forget about everything else that has going on with Sirona...there is much more than just the SGLT2
SGLT2 vs Skin Lightener (beides "Produkte" von Sirona Biochem)
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
For me my main reason for first investing in Sirona was the Skin Lightener. This is a fast to market compound with very few hoops to jump through to get to approval. The SGLT2 as great of a product it is, will still be a wait till anything comes from it (wheres biotechguy when you need him lol). Ive said it many times over the last few days but one more time wont hurt...A skin lightener deal for one or both of our 2 skin lightener compunds will blow the lid off this thing. Johnson will be wondering where the hell his 4m share wall went (an assumption on my part obviously).
Rumours are that interest is VERY high for the skin compounds as some are fighting for exclusivity of one of them. Depending on the timing for a deal, SBM wont need dilution as I see this bringing alot of money in up front and much more in royalty payments...CCH and J&J connection maybe? I dunno but dont forget about everything else that has going on with Sirona...there is much more than just the SGLT2
Insiderverkauf:
Was ist mit dieser Firma los.
Insiderverkauf während eines PP.
Insiderverkauf nach dem Wanbang Pharma Deal
Dumm & Dümmer!!!
Was ist mit dieser Firma los.
Insiderverkauf während eines PP.
Insiderverkauf nach dem Wanbang Pharma Deal
Dumm & Dümmer!!!
Zitat von Jon_Schnee: Gestern Company per Mail angeschrieben. Antwort nach 5 Stunden. Das nenn ich mal Aktionär freundlich
Hier mal die Frage:
Dear All
I am shareholder.
Congratulation, very good deal!
Could you tell me when do you get the first milestone payment & what is the value of it?
Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
And how long are you funded without this deal?
best regards
xxxxxxxxxxxxx
Antwort:
Hi xxxxx,
Thank you for your message.
I'm sorry but the information included in the news release is all that we are making public regarding the terms of the agreement.
What may be valuable to note however is that Wanbang Pharma will be paying for all future studies towards clinical approval of our SGLT2 Inhibitor. With each new piece of data created by Wanbang, the value of our compound grows exponentially for the rest of the world. We know that previous SGLT2 compounds acheiving success in phase 2 and 3 have earned transaction fees in the hundreds of millions of dollars.
Sirona will not assume any financial risk or resource burden in the future studies, while enjoying the all of the value created by Wanbang's very capable development teams. We couldn't be more excited about the future for this compound.
Currently we have roughly two months in the bank and we remain focused on executing our business plan and creating significant value for our shareholders.
Thank you again for your interest.
Antonia Issa, BA, MBA
Communications Manager
aissa@sironabiochem.com
D 604.282.6065
Sirona Biochem Corp.
605-889 West Pender Street
Vancouver, BC V6C 3B2
M 604.641.4466
F 604.608.5471
TF 1.888.SIRONA1 (7476221)
TSX-V: SBM
www.sironabiochem.com
Gestern Company per Mail angeschrieben. Antwort nach 5 Stunden. Das nenn ich mal Aktionär freundlich 
Hier mal die Frage:
Dear All
I am shareholder.
Congratulation, very good deal!
Could you tell me when do you get the first milestone payment & what is the value of it?
Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
And how long are you funded without this deal?
best regards
xxxxxxxxxxxxx
Hier mal die Frage:
Dear All
I am shareholder.
Congratulation, very good deal!
Could you tell me when do you get the first milestone payment & what is the value of it?
Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
And how long are you funded without this deal?
best regards
xxxxxxxxxxxxx
gutes Posting -> SH:
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
I was starting to have my doubts that this company would actually be able to close any deals that generated revenue. I think we are all starting to see the possibilities a bit mroe clearly now.
I'm especially pleasantly surprised that the first deal seems to reveal a very cleaver strategy. I had assumed that Sirona would just license the SGLT2 inhibitor out at a pre-clinical stage, which means the value would be fairly limited compared to a drug already in clinical trials. The Wanbang/Fosun deal suggests a much more ambitious plan, where the deal generates clinical trial data that adds a whole lot of value to the SGLT2 inhibitor. In effect, Sirona traded the rights in China for a modest amount of money plus the possibility of clinical trial data that could make the product worth $100 million or more. We would never have gotten a deal like that from big pharma.
From FierceBiotech:
"Meanwhile, China's Shanghai Fosun Pharmaceutical is coming on strong for next year, Forbes says. Controlled by Chinese billionaire Guo Guangchang, the company has been snapping up stakes in other drugmakers and setting up joint ventures with the likes of Lonza."
http://www.fiercepharma.com/story/csl-sun-pharma-rank-absolu…
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
I was starting to have my doubts that this company would actually be able to close any deals that generated revenue. I think we are all starting to see the possibilities a bit mroe clearly now.
I'm especially pleasantly surprised that the first deal seems to reveal a very cleaver strategy. I had assumed that Sirona would just license the SGLT2 inhibitor out at a pre-clinical stage, which means the value would be fairly limited compared to a drug already in clinical trials. The Wanbang/Fosun deal suggests a much more ambitious plan, where the deal generates clinical trial data that adds a whole lot of value to the SGLT2 inhibitor. In effect, Sirona traded the rights in China for a modest amount of money plus the possibility of clinical trial data that could make the product worth $100 million or more. We would never have gotten a deal like that from big pharma.
From FierceBiotech:
"Meanwhile, China's Shanghai Fosun Pharmaceutical is coming on strong for next year, Forbes says. Controlled by Chinese billionaire Guo Guangchang, the company has been snapping up stakes in other drugmakers and setting up joint ventures with the likes of Lonza."
http://www.fiercepharma.com/story/csl-sun-pharma-rank-absolu…
Trading Spotlight
Bei Stockhouse.com wird Sirona im Gegensatz zu hier disktutiert:
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…
So viel zu den unqualifizierten Postings 
Zitat von Datteljongleur: Sehr beeindruckend. Echt.
Scheint gerade der neueste "Trend" zu sein, diese Art von Klitschen zu pushen.
Zitat von VanGillen: Ergebnis/Aktie (in EUR) n.a. n.a. n.a.
KGV n.a. n.a. n.a.
Dividende/Aktie (in EUR) n.a. n.a. n.a.
Dividendenrendite (in %) n.a. n.a. n.a.
Sehr beeindruckend. Echt.
Zitat von nordlicht100: Ich möchte mal wissen, wie risikobereit (oder verzweifelt?!) man eigentlich sein muss, um solche Aktien zu kaufen!
Ich meine, die Dinger kann man ja eigentlich nicht mal mehr als Penny-Stock begreifen.
Antwort auf Beitrag Nr.: 45.278.759 von Jon_Schnee am 19.08.13 16:36:42PS. Der China Partner ist Klasse
About Wanbang Pharma
Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.
About Wanbang Pharma
Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.
Zitat von Jon_Schnee: Was ist der Deal Wert? US$9.5M & Royalties:
Nicht schlecht für eine Marktkapitalisierung von US$15M
In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
Und der Deal ist "nur" auf China beschränkt. Weiter SGLT2 Inhibitor Deals können jederzeit noch kommen.
Ich warte aber vorallem auf den Skin Lightening Deal
hier geht dann richtig die Post ab.
Antwort auf Beitrag Nr.: 45.278.593 von Jon_Schnee am 19.08.13 16:14:31Was ist der Deal Wert? US$9.5M & Royalties:
Nicht schlecht für eine Marktkapitalisierung von US$15M
In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
Nicht schlecht für eine Marktkapitalisierung von US$15M
In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
Durchsuchen
Sirona Biochem
